KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm phase II trial to evaluate the efficacy, safety and
tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be
enrolled and receive protocol defined therapies until progressive disease, unacceptable
toxicity or withdrawal of informed consent. Tumor assessment will be performed according to
RECIST 1.1 criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University